Drugs / FHND9041
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06521034 | Jun 2019 → May 2021 | non-small cell lung carcinoma | Yongchang Zhang | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06759857 | Aug 2021 → Mar 2025 overdue | non-small cell lung carcinoma | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FHND9041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06759857 ↗ |
| Action | Inhibit | “FHND-9041 capsule is a novel third-generation EGFR inhibitor targeting EGFR-sensitive mutations.” NCT06521034 ↗ |
| Route | Oral | “Participants will take an 80 mg oral dose once daily until disease progression, intolerable toxicity, or meeting other study-defined discontinuation criteria.” NCT06759857 ↗ |
| Target | EGFR | “FHND-9041 capsule is a novel third-generation EGFR inhibitor targeting EGFR-sensitive mutations.” NCT06521034 ↗ |